{
  "abstract": "More than half of patients with early-stage non-small cell lung cancer (NSCLC) experience recurrent disease following definitive therapy. Targeted therapies have demonstrated significant and clinically meaningful benefit in EGFR-, ALK-, or RET-driven early-stage NSCLC. There are, however, no approved therapies for early-stage KRAS G12C-mutant NSCLC, presenting a potential therapeutic opportunity. Olomorasib is a potent, highly selective next-generation KRAS G12C inhibitor(i) demonstrating promising antitumor and intracranial activity with a manageable safety profile in KRAS G12C-mutant metastatic NSCLC. Preclinical studies have shown that KRAS G12C inhibition reverses KRAS-mediated immune suppression, creating an inflamed tumor microenvironment responsive to immunotherapy. Combining olomorasib and immune checkpoint inhibitors is supported by synergistic and additive effects in preclinical and clinical setting. SUNRAY-02 is a 2-part global, placebo-controlled phase III study recruiting patients with stage II-III KRAS G12C-mutant NSCLC following definitive therapy. Part A patients with resected NSCLC receive olomorasib or placebo in combination with pembrolizumab, while Part B patients with unresectable NSCLC receive olomorasib or placebo in combination with durvalumab. Combination treatment continues for approximately 1-year, followed by olomorasib or placebo monotherapy, completing up to 3-years of treatment. This trial addresses a critical treatment gap in KRAS G12C-mutant early-stage NSCLC.\n\nClinical trial registration: NCT06890598 (www.clinicaltrials.gov); EudraCT: 2024-512302-25–00.",
  "abstract_shown": true,
  "affiliations": [
    "Thoracic Oncology, Department of Medicine, MSKCC - Memorial Sloan Kettering Cancer Center, New York, NY, USA",
    "Thoracic Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA",
    "Division of Thoracic Surgery, UCLA - David Geffen School of Medicine, Los Angeles, CA, USA",
    "Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre (VUmc), Amsterdam, The Netherlands",
    "Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA",
    "Department of Medical Oncology, Institut Català d’Oncologia (ICO), Barcelona, Spain",
    "Department of Thoracic/Head & Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA",
    "Lung Unit, The Royal Marsden Hospital - NHS Foundation Trust, London, UK",
    "Department of Medicine, Hematology Oncology Section, Thoracic Oncology Program the University of Chicago, Chicago, IL, USA",
    "Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, USA",
    "Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea",
    "Thoracic Oncology Department, Centre Hospitalier Universitaire - Univ Toulouse, Toulouse, France",
    "Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany",
    "Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany",
    "Eli Lilly and Company, Indianapolis, IN, USA",
    "Guangdong Lung Cancer Institute, Guangdong Province People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China"
  ],
  "article_type": "methods article",
  "arxiv": null,
  "author_total": 19,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Jamie Chaft",
      "orcid": "0000-0002-5838-9982"
    },
    {
      "affs": [
        2
      ],
      "name": "Jay M. Lee",
      "orcid": "0000-0003-3715-6749"
    },
    {
      "affs": [
        3
      ],
      "name": "Suresh Senan",
      "orcid": "0000-0003-3995-2204"
    },
    {
      "affs": [
        4
      ],
      "name": "Joel W. Neal",
      "orcid": "0000-0003-3119-9334"
    },
    {
      "affs": [
        5
      ],
      "name": "Ernest Nadal",
      "orcid": "0000-0002-9674-5554"
    },
    {
      "affs": [
        6
      ],
      "name": "Marcelo V. Negrao",
      "orcid": "0000-0001-8938-6699"
    },
    {
      "affs": [
        7
      ],
      "name": "Sanjay Popat",
      "orcid": "0000-0003-2087-4963"
    },
    {
      "affs": [
        8
      ],
      "name": "Marina C. Garassino",
      "orcid": "0000-0002-3821-5598"
    },
    {
      "affs": [
        9
      ],
      "name": "Jhanelle E. Gray",
      "orcid": "0000-0003-1304-7062"
    },
    {
      "affs": [
        10
      ],
      "name": "Se-Hoon Lee",
      "orcid": "0000-0002-9219-3350"
    },
    {
      "affs": [
        11
      ],
      "name": "Julien Mazieres",
      "orcid": "0000-0002-5921-7613"
    },
    {
      "affs": [
        12,
        13
      ],
      "name": "Michael Thomas",
      "orcid": "0000-0001-9511-055X"
    },
    {
      "affs": [
        14
      ],
      "name": "Martin Benes"
    },
    {
      "affs": [
        14
      ],
      "name": "Hui Liu",
      "orcid": "0009-0005-2251-0639"
    },
    {
      "affs": [
        14
      ],
      "name": "Jian Liu",
      "orcid": "0009-0005-1417-4110"
    },
    {
      "affs": [
        14
      ],
      "name": "Qinli Lily Ma",
      "orcid": "0000-0002-2197-0087"
    },
    {
      "affs": [
        14
      ],
      "name": "Grace Segall",
      "orcid": "0000-0002-4942-7633"
    },
    {
      "affs": [
        14
      ],
      "name": "Tarun Puri",
      "orcid": "0000-0003-2399-4362"
    },
    {
      "affs": [
        15
      ],
      "name": "Yi-Long Wu",
      "orcid": "0000-0002-3611-0258"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7nknv9yxg766x.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2736401",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13733190/",
  "id": "7nknv9yxg766x",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2736401",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Clinical Trial Protocol"
    ],
    [
      "heading",
      "Method"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7216099817",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2736401?needAccess=true",
  "pmcid": "PMC13733190",
  "pmid": "42823821",
  "published": "2026-10-01",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/7nknv9yxg766x.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:23:02Z",
      "native_id": "PMC13733190",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2736401"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy",
  "title_text": "SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:23:02Z",
  "url": "https://research.draconitic.com/paper/7nknv9yxg766x",
  "venue": "Future Oncology",
  "versions": []
}